SARS‐CoV‐2 PL pro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment
ChemistryOpen · 2024
DOI: 10.1002/open.202400091 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistryOpen, 2024. Verfasst von Sara Protić und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry, University of Belgrade, Studentski Trg 12-16, Belgrade, Serbia. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Drug Repositioning, Fidaxomicin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia, Ministry of Science, Technological Development and Innovation of Republic of Serbia.
Abstract (Originalsprache)
The emergence of drug‐resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID‐19 pandemic. While de novo drug development is a time‐consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS‐CoV‐2 papain‐like protease inhibitor. This study extends those findings by investigating fidaxomicin‘s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS‐CoV‐2, given its promising in vitro antiviral activity and favorable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Chemistry, University of Belgrade, Studentski Trg 12-16, Belgrade, Serbia.
- Institute of Chemistry, Technology and Metallurgy, University of Belgrade, Njegoševa 12, Belgrade, Serbia.
- Institute for Multidisciplinary Research, University of Belgrade, Kneza Višeslava 1, Belgrade, Serbia.
- Laboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, Belgrade, Serbia.
- Laboratory for Plant Molecular Biology, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, Belgrade, Serbia.
- Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States.
Förderung
- Science Fund of the Republic of Serbia
- Ministry of Science, Technological Development and Innovation of Republic of Serbia
Zitieren
APA
Protić, S., Crnoglavac Popović, M., Kaličanin, N., Prodanović, O., Senćanski, M., Milićević, J., Stevanović, K., Perović, V., Paessler, S., Prodanović, R., & Glišić, S. (2024). SARS‐CoV‐2 PL pro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment. ChemistryOpen. https://doi.org/10.1002/open.202400091
Vancouver
Protić S, Crnoglavac Popović M, Kaličanin N, Prodanović O, Senćanski M, Milićević J, et al. SARS‐CoV‐2 PL pro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment. ChemistryOpen. 2024. doi:10.1002/open.202400091
BibTeX
@article{Proti2024,
author = {Protić, Sara and Crnoglavac Popović, Milica and Kaličanin, Nevena and Prodanović, Olivera and Senćanski, Milan and Milićević, Jelena and Stevanović, Kristina and Perović, Vladimir and Paessler, Slobodan and Prodanović, Radivoje and Glišić, Sanja},
title = {SARS‐CoV‐2 PL pro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment},
journal = {ChemistryOpen},
year = {2024},
doi = {10.1002/open.202400091}
}
EUVIMED